Coherus Oncology

What Coherus Oncology does

Coherus Oncology is a commercial-stage biopharmaceutical company headquartered in Redwood City, California, that develops and commercializes immuno-oncology therapies. The company's core technology is a PD-1 inhibitor immunotherapy platform centered on toripalimab-tpzi, marketed as LOQTORZI. LOQTORZI is the only FDA-approved therapy for nasopharyngeal carcinoma (NPC), a rare head and neck cancer, establishing the company's primary commercial footprint in a defensible niche oncology indication.

Beyond LOQTORZI, Coherus is advancing a pipeline of pipeline-stage immuno-oncology candidates, including tagmokitug (ILT4 blockade), casdozokitug/SRF388 (IL-27 targeting), and ZM008 (anti-LLT1 monoclonal antibody), each being evaluated in Phase 1/2 trials across multiple solid tumor indications such as hepatocellular carcinoma (HCC), colorectal, head and neck, non-small cell lung, renal cell carcinoma, and urothelial cancers. The pipeline is being advanced both independently and through clinical collaborations with partners including Johnson & Johnson and Zumutor Biologics.

The company operates a traditional specialty-pharma business model, generating revenue through commercial sales of LOQTORZI via specialty pharmacy channels and direct relationships with oncology treatment centers and hospitals. LOQTORZI net revenue doubled from $19.1 million in 2024 to $40.8 million in 2025, with Q1 2026 net revenue of $11.8 million representing 61% year-over-year growth. The company is publicly traded on NASDAQ under the ticker CHRS, carries approximately 72.82% institutional ownership, and is currently operating with $167.0 million in cash and marketable securities as of Q1 2026, having reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024–2025.

Name

Coherus Oncology

Legal name

Coherus Oncology, Inc.

Website

https://coherusoncology.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

Coherus Oncology is a commercial-stage biopharmaceutical company developing and commercializing immuno-oncology therapies, with LOQTORZI as the only FDA-approved treatment for nasopharyngeal carcinoma and a pipeline of checkpoint inhibitor candidates for solid tumors.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Immuno-oncology drugs
• PD-1 inhibitor therapy
• Oncology drug development
• Cancer immunotherapy
• Rare cancer treatment

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

1. LOQTORZI Product Sales: Commercial sales of FDA-approved PD-1 inhibitor LOQTORZI (toripalimab-tpzi) for nasopharyngeal carcinoma. Revenue doubled from $19.1M in 2024 to $40.8M in 2025. Q1 2026 generated $11.8M net revenue representing 61% year-over-year growth.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Coherus Oncology develops and commercializes immuno-oncology therapies, with LOQTORZI (toripalimab-tpzi) as its lead FDA-approved PD-1 inhibitor for nasopharyngeal carcinoma (NPC)—the only FDA-approved therapy for this rare cancer indication. The company also advances pipeline candidates including tagmokitug (ILT4 blockade), casdozokitug/SRF388 (IL-27 targeting), and ZM008 (anti-LLT1) for multiple solid tumor indications including hepatocellular carcinoma, colorectal, head and neck, lung, renal cell carcinoma, and urothelial cancers.

Product overview

Coherus Oncology is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), which is the only FDA-approved therapy for nasopharyngeal carcinoma. The company is developing multiple pipeline candidates including tagmokitug, casdozokitug (SRF388), and ZM008 for various solid tumor indications such as hepatocellular carcinoma, colorectal, head and neck, lung, renal cell carcinoma, and urothelial cancers.

Differentiator

Problem solved

Functional benefit

Brands

• LOQTORZI (toripalimab-tpzi): FDA-approved PD-1 inhibitor therapy for nasopharyngeal carcinoma (NPC). The only FDA-approved therapy for this rare cancer indication.

Products and services

• LOQTORZI (toripalimab-tpzi)
• tagmokitug
• casdozokitug (SRF388)
• ZM008

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Zumutor BiologicscoreStrategic or Co-development Partner · 23 June 2026Clinical collaboration and supply agreement to conduct Phase 1 trial evaluating ZM008 (novel NK checkpoint anti-LLT1 monoclonal antibody) in combination with LOQTORZI (toripalimab-tpzi) in patients with multiple solid tumors including colorectal, head and neck, NSCLC, clear cell renal cell carcinoma, and urothelial cancers. Trial will enroll up to 45 patients across dose-escalation and expansion cohorts in the United States. Each company retains all commercial rights to their respective compounds.
• Johnson & JohnsoncoreStrategic or Co-development Partner · 1 January 2026Clinical supply agreement signed for combination study with J&J's T-cell engager pasritamig in metastatic castration resistant prostate cancer. Pipeline advancement includes planned combination study with J&J's experimental compound.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• BeiGene: Develops Tislelizumab, a PD-1 inhibitor approved in multiple geographies for oncology indications. Comparable as a direct PD-1 competitor with similar novel-mechanism antibody positioning and global commercial ambitions.
• CStone Pharmaceuticals: Develops sugemalimab, a PD-L1 inhibitor approved in multiple oncology indications. Comparable as a smaller-cap PD-(L)1 antibody peer with overlapping oncology indications and combination-development focus.
• Shanghai Junshi Biosciences: Originator of toripalimab (LOQTORZI's active ingredient). Directly comparable as the molecule's developer and a PD-1 antibody peer with similar oncology indications and Asia/US commercialization footprint.
• Regeneron Pharmaceuticals: Markets Libtayo (cemiplimab), a PD-1 inhibitor approved for cutaneous squamous cell carcinoma and other oncology indications. Comparable as a direct PD-1 class competitor with a similar oncology-only commercial focus.
• Innovent Biologics: Co-develops Tyvyt (sintilimab) with Eli Lilly, a PD-1 inhibitor approved across multiple oncology indications, including indications overlapping with LOQTORZI's pipeline. Comparable as a PD-1 antibody peer with a China-origin, multi-indication strategy.

Emerging players

• Genmab: Antibody-focused oncology biotech with PD-L1/PD-1 and next-generation immuno-oncology assets. Comparable as a peer developing novel antibody-based oncology therapeutics, particularly in combination settings.
• MacroGenics: Clinical-stage oncology biotech developing antibody-based therapeutics including checkpoint inhibitors and immune-engagers. Comparable as a smaller-cap immuno-oncology peer with pipeline assets in similar combination strategies.

Broad incumbents

• Bristol-Myers Squibb: Markets Opdivo (nivolumab), the second major PD-1 inhibitor with broad oncology label coverage. Directly comparable as a PD-1 class competitor and broader oncology commercial-stage incumbent.
• Merck & Co. Developer of Keytruda (pembrolizumab), the leading PD-1 inhibitor approved across numerous oncology indications. Comparable as a broad incumbent in the immuno-oncology/PD-1 class that Coherus' LOQTORZI competes within.
• AstraZeneca: Markets Imfinzi (durvalumab), a PD-L1 inhibitor approved across multiple oncology indications including hepatocellular carcinoma. Comparable as a large-cap immuno-oncology incumbent with overlapping indications like HCC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Coherus_Bio
• LinkedInlinkedin.com/company/coherus-oncology

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coherus Oncology